Patents by Inventor Matthew G. Cottingham

Matthew G. Cottingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970709
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orfl, E4Orf2 and E4Orf3 coding regions from AdY25.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 30, 2024
    Assignee: Oxford University Innovation Limited
    Inventors: Sarah C. Gilbert, Adrian V S Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
  • Publication number: 20220220507
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orfl, E4Orf2 and E4Orf3 coding regions from AdY25.
    Type: Application
    Filed: January 28, 2022
    Publication date: July 14, 2022
    Applicant: Oxford University Innovation Limited
    Inventors: Sarah C. Gilbert, Adrian VS Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
  • Patent number: 11306325
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 19, 2022
    Assignee: Oxford University Innovation Limited
    Inventors: Sarah C. Gilbert, Adrian V S Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
  • Publication number: 20190175716
    Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25.
    Type: Application
    Filed: June 23, 2017
    Publication date: June 13, 2019
    Inventors: Sarah C. Gilbert, Adrian VS Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
  • Publication number: 20160304582
    Abstract: The invention relates to the use of a molecular adjuvant to generate an improved immune response in a host. Over recent years extensive research and development has been undertaken in the development of “vectored vaccines” which can be used as vaccine delivery systems. Vectored vaccines include DNA vectors and recombinant viral and bacterial vectors, which are engineered to express an antigen of interest. The invention provides a nucleic acid construct encoding a protein fusion between an antigen and an invariant chain molecule.
    Type: Application
    Filed: December 3, 2014
    Publication date: October 20, 2016
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Adrian Vivian Sinton Hill, Alexandra J. Spencer, Benedict R. Halbroth, Matthew G. Cottingham